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Abstract. Our understanding of PD pathophysiology is vastly improved compared to the situation 20 years ago. We have
identified the major genetic risks for PD, we now have far more representative animal models of the disease, and we
can be inspired by the early successes of others using Antisense Oligonucleotide and vaccination approaches in other
neurodegenerative diseases. We also have a broad range of repurposed drugs showing the first signals of potential efficacy
in the translational pipeline which are being driven forward through the various clinical trial stages. We believe we can be
optimistic that the next 20 years will be a time for major breakthroughs towards the discovery of therapies that may slow,
stop, or reverse PD.
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INTRODUCTION
No one has a crystal ball, but it is increasingly
likely that the next 20 years will see great progress
in the search for approaches to slow down, stop
or reverse the pathological processes of Parkinson’s
disease (PD). Our understanding of PD pathophysiol-
ogy, the development of better laboratory models of
PD, combined with data emerging from both the lab
and from early phase clinical trials, (in the authors’
view) strongly justifies sending this message of hope
to our patients.
The evolution of treatments from the initial lab-
oratory discovery to routine clinical prescription is
however frustratingly slow, and a realistic prediction
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of where we will be in 20 years has to consider
this. Investigator initiated trials depend on repetitive
cycles of funding application and committee review,
and this can add to the time needed to pass through
the necessary clinical trial stages. Even evaluation of
commercially backed products can seemingly take an
excessively long time to run the gauntlet from bench
to bedside.
In the search for a symptomatic therapy, it is easy
to define a threshold of response and quickly test sin-
gle and multiple ascending doses over a relatively
short duration to identify safety, tolerability and effi-
cacy/futility. In contrast, in the search for effective
therapies that may have disease modifying or even
neurorestorative properties, it may take months or
years for a signal to become detectable in view of
the generally slow rate of progression of PD, and
therefore can require large sample sizes to identify
small but potentially important effect sizes over the
longer term. Distinguishing between a transient, i.e.,
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symptomatic effect from a long term, cumulative
effect can be extremely challenging. The different
trial designs that might be most suitable in the search
for disease modifying therapies have been recently
highlighted [1], but there is still no agreement about
which is the best and most pragmatic way of demon-
strating this signal of effect. In short, there is an
inevitable compromise between cost, trial duration,
expediency and power especially in the search for
agents with potentially small effect sizes.
For some approaches, we may however already be
a fair distance down the 20 year road towards disease
modifying drug discovery and development, which
will be the focus of this review. We will highlight
the drugs and candidate molecules that appear to be
surviving and/or emerging as the most likely disease
modifying approaches for PD, despite the challenges
described above. Finally we also speculate on how
this field will evolve in the next 20 years.
PRECISION MEDICINE MAY HAVE
BROAD APPLICATION
LRRK2 (leucine rich repeat kinase 2)
The discovery of genetic risk factors for PD has
been effective in elucidating precise pathways to new
therapeutic targets. Autosomal dominant mutations
in the LRRK2 gene tend to cause PD through a toxic
gain of function [2], which in turn has lead to an
ongoing focus on agents that inhibit LRRK2 thereby
aiming directly at the cause for this population of
patients.
However, attempts to exploit LRRK2 inhibitors
thus far have been thwarted by the observation
that primates exposed to LRRK2 inhibitors develop
lung toxicity [3]. Better delivery mechanisms may
be one route to overcome this hurdle, or alterna-
tively approaches to LRRK2 may exploit antisense
oligonucleotide technology, as has already been
shown to be effective in spinal muscular atrophy
[4]. This approach (already being pursued commer-
cially) could specifically target brain LRRK2 activity
via intrathecal administration (e.g., using minipumps
as used in intrathecal Baclofen delivery) or other
brain selective delivery mechanisms (e.g., convection
enhanced delivery [5]).
But what if brain LRRK2 activity is not actu-
ally the relevant target? There are LRRK2 variants
associated with an elevated risk of PD in the spo-
radic PD population, suggesting this enzyme may be
a target for a larger population of PD patients [6].
However some of these variants are robustly asso-
ciated with PD but without appearing to have any
impact on brain LRRK2 gene expression [7]. Other
factors may influence LRRK2 activity other than
gene expression, however reflecting on this and also
considering parallel work revealing the relevance of
LRRK2 to Crohn’s disease as well as mycobacte-
rial infections [8–10], we might speculate that PD
pathogenesis may (in some individuals) follow an
interaction between LRRK2 activity in the gut, the
gut microbiome, and/or gut alpha synuclein. Fur-
ther data will be needed to explore this, but if so,
our LRRK2 inhibitors may turn out to be effec-
tive orally, and maybe not only in patients with
Mendelian LRRK2 mutations, but even among those
with LRRK2 polymorphisms which may increase the
risk for developing sporadic PD.
GBA (Glucosidase beta acid)
Along similar lines, the identification of a treat-
ment to combat PD in patients with mutations in the
GBA gene, may also have relevance to patients with
sporadic forms of PD. The enzyme glucocerebrosi-
dase (GCase), encoded by this gene, plays a role in the
normal trafficking and/or processing of alpha synu-
clein which is reduced in GBA mutation carriers.
Exactly how GCase interacts with alpha synuclein
to cause PD in some people with GBA mutations is
not yet precisely clear but several plausible theories
exist [11]. A bidirectional relationship occurs with
misfolded alpha synuclein itself impacting on GCase
function [12] thus this enzyme may too be a relevant
target in patients with sporadic forms of PD, in whom
low GCase activity can also be seen [13]. Chaperones
that boost this enzyme include Ambroxol [14, 15], a
licensed drug for lung surfactant deficiency, and in
Europe also available as a cough linctus. Importantly,
studies are nearing completion to identify whether PD
patients can tolerate the dose required to penetrate the
central nervous system and act as a GCase chaperone.
Beyond this, the potential efficacy of Ambroxol will
undoubtedly be formally explored, but the fact that
a GCase chaperone (e.g., Ambroxol) may in paral-
lel also act as an inhibitor of GCase activity could
prove to be a stumbling block in developing it as a
new therapy for PD [16].
Irrespective of the success or failure of Ambroxol,
given the emerging importance of GCase [17] it is
important to note that other novel GCase chaperones
have also been identified [18]. Some of these may
have more favorable profiles of actions and brain
T. Foltynie and J.W. Langston / Therapies to Slow, Stop, or Reverse PD S117
penetrance than Ambroxol, and in view of the poten-
tial effect on alpha synuclein misfolding, we can
expect that they will likely require clinical trial evalu-
ation not only in GBA patients but also in the sporadic
PD population.
SLOWING THE SPREAD OF ALPHA
SYNUCLEIN PATHOLOGY
There is a mantra that disease modifying treat-
ments must be initiated early if they are to be of any
use in preventing disease progression. This is because
post mortem specimens suggest that >50% of SNc
dopaminergic neurons are already lost by the time
that patients present with the classical motor features
of the disease [19]. Given that there are many effective
symptomatic treatments to help the motor, dopamin-
ergic deficits in PD, it can be argued that the important
unmet needs in PD relate to cognitive, speech, gait
and balance difficulties and autonomic failure. In this
case any treatment that prevented onset/worsening of
these symptoms, would be highly relevant even in
patients with established motor PD, and would be
addressing the major challenges that patients face in
its long-term management. From another perspective,
since many of these “non-motor” features of PD may
precede the onset of motor symptoms, we may have
an even earlier window to start therapy, and have an
opportunity to slow or stop the development of even
the first motor symptoms of PD.
Preventing propagation of pathology from one
neuron to the next (and thus in theory preventing
the onset of these disabling non-motor symptoms)
may be accomplished by the use of antibodies with
specificity for pathogenic species of alpha synuclein.
This approach could be boosted if publication of
the BAN2401 antibody data in Alzheimer’s disease
[20] aligns with the results announced at the 2018
Alzheimer’s association International Conference.
Biogen, Roche/Prothena and Affiris are all invest-
ing in major trials of alpha synuclein antibody or
vaccination programs to try and reproduce this type
of success in PD. The success of these projects will
depend at least in part on 1) ensuring that sufficient
antibody accesses the brain parenchyma, 2) that the
toxic species of alpha synuclein is visible to the anti-
body at the trans-synaptic site, and 3) that there is
sufficient specificity of the antibody to avoid inter-
ference with the synaptic functions of normal alpha
synuclein (which have yet to be fully elucidated).
This far, it appears that CNS penetration is indeed
adequate with the antibodies currently in trials, and
that serum alpha synuclein levels fall following sus-
tained antibody administration [21, 22]. As yet the
studies currently recruiting are inevitably prioritis-
ing safety and tolerability while trying to identify the
optimal dose, and are unlikely to be completed until
2021/2022.
Beyond this, the companies will have to look care-
fully at the emerging data to decide whether a strategy
of enrichment (i.e., selecting patients with specific
genotypes or according to their predicted rate of pro-
gression [23]) might be advantageous, and/or whether
to risk extending trial eligibility to patients with




An alternative to stopping the spread of pathol-
ogy, is to try and help neurons continue to function
despite the presence of pathological alpha synuclein,
i.e., to provide some form of trophic support. There
are several classes of drugs being repurposed (i.e.,
already confirmed to be safe for human use), which
may achieve this.
There has been a lot of publicity surrounding the
potential of Glucagon-like peptide 1 (GLP-1) recep-
tor agonists in PD [24, 25]. These drugs are licensed
for the treatment of Type 2 diabetes (T2DM) and have
neuroprotective properties across the whole range of
animal models of PD, including 2 alpha synuclein
models. There is some evidence that this action may
relate to an improvement in brain insulin signaling
(reviewed in [26]) which enhances Akt activity (a crit-
ical protein involved in cell survival processes) while
additional data indicate these drugs may also act in
parallel through a positive effect on neuroinflamma-
tion [27]. Indeed, the increased risk of developing PD
among T2DM patients may be ameliorated according
to the choice of anti-diabetic agent used [28].
Within a few years, we will know whether this class
of drug fulfills its promise as plans for a phase 3 trial
of exenatide are afoot, and there is growing interest in
exploring other drugs in this class for their potential
disease modifying properties (NCT02953665, NCT
03439943, NCT03659682). Enhancing the potency
of existing anti-diabetic medications is therefore an
appealing proposition for a number of commercial
entities. Neuraly have modified the original GLP-
1 receptor agonist, exenatide to enhance its brain
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penetration and reduce its immunogenicity, while
Peptron have developed a separate novel slow release
exenatide formulation.
Other drugs which may enhance neuronal sur-
vival are also becoming major avenues of interest.
Ursodeoxycholic acid (UDCA) is a licensed treat-
ment for primary biliary cirrhosis and emerged as
the most promising agent from a drug screen using
fibroblasts from parkin and LRRK2 patients [29,
30]. Similar to exenatide, UDCA appears to have
an action on the protein kinase Akt, with a conse-
quent mitochondrial rescue effect. Whether simply
recommending a specific programme of high inten-
sity training might be an alternative way of engaging
the same pathways is also of some interest [31].
Another agent, Nilotinib, a c-abl inhibitor used in
chronic myelocytic leukemia also has actions on
alpha synuclein toxicity and apoptotic pathways of
relevance to PD [32, 33], and is the subject of formal
safety/tolerability evaluation while trials of Inosine
and Isradipine will soon report whether any signals
of efficacy associated with their use may encourage
their further development.
Attention has also been drawn to agonists of the
beta adrenoceptor (Salbutamol, Clenbuterol) follow-
ing the observation that 1) patients on these drugs
appear to have a lower risk of developing PD, 2)
patients on beta receptor antagonists appear to have a
higher risk of PD, 3) alpha synuclein transcription can
be modulated by beta agonists [34]. Whether these
data fully account for the known influence of smok-
ing on PD risk (smoking may lead to increased use of
beta agonists) remains a subject of debate, indeed the
epidemiological evidence has failed to be replicated
in a recent study [35], however given the long term
known safety data, if these drugs indicate any evi-
dence of neuroprotection in early clinical trials, rapid
progression to phase 3 could be easily envisaged.
CONFRONTING THE PROBLEM “AT
SOURCE”
Immunomodulation
Neuroinflammation has been on the radar as a
factor involved in PD on and off for the last 30
years, and it is yet again gaining attention. Interest-
ingly, there is evidence that alpha synuclein may turn
out to be a central player in this immune response.
Indeed T cells from patients with PD recognize alpha
synuclein peptides [36], suggesting that an individ-
ual’s immune response to pathogenic forms of alpha
synuclein could play a key role in disease progres-
sion. On a related note, alpha synuclein itself may
even play a role in the innate immune response in
the gut [37]. Either way, there is increasing interest
in immunomodulatory therapies to prevent PD, and
there are a host of existing immunosuppressive agents
including, e.g., Azathioprine and Sargramostim [38]
that are being considered as potential candidates for
slowing disease progression.
The gut microbiome
At the same time, there is growing evidence of
an infectious trigger for this immune-dysregulation.
For example, alpha synuclein transgenic mice can
be spared onset of pathology if bred in germ free
environments or if exposed to broad spectrum antibi-
otics. Furthermore colonization of the gut from fecal
bacteria from PD patients greatly exacerbates alpha
synuclein pathology in the brains of these animals
[39]. A link between metabolites produced by gut
bacteria and brain inflammation has also been iden-
tified [40], so shouldn’t we already be actively
trying to interfere with this gut/brain axis to pre-
vent neurodegeneration? Giving encapsulated fecal
transplants from healthy individuals to people with
PD are currently being considered (this is already an
accepted treatment for gastrointestinal illnesses like
C-difficile). Extending the parallel interests between
diabetes processes and neurodegeneration, it is inter-
esting to observe that encapsulated fecal transplants
have also be shown to improve peripheral insulin sen-
sitivity [41] possibly offering another clue regarding
the genesis of PD.
How this might ultimately translate to PD thera-
peutics needs to be considered. Useful responses must
depend somewhat on whether the alpha synuclein
pathology is already established to the extent that “the
horse has already bolted” by this stage? However an
alternative possibility is that ongoing gut pathology
may continue to seed abnormal alpha synuclein to the
brain via vagal transmission or short chain fatty acid
signalling and contribute to ongoing neurodegenera-
tion over the longer term. Given that the use of fecal
transplants to treat diseases is already being explored
in patients with motor neuron disease, it is therefore
highly likely that there will be a range of attempts
at manipulating the gut microbiome over the coming
years in PD patients, to try and close the stable door,
lest more alpha synuclein oligomeric horses will be
racing to other areas of the central and peripheral
autonomic nervous systems.
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NANOTECHNOLOGY: SCIENCE FICTION
OR FACT?
The grand vision would be to develop a therapy that
would accurately target alpha synuclein pathology,
dissolve the toxic aggregates and push the equilib-
rium back towards normal monomeric alpha synu-
clein. Would this sci-fi dream ultimately be the defini-
tive cure for PD? With the aptly named, graphene
quantum dots (GQDs), perhaps this dream is right
in from of us. These nanoparticles have been shown
to penetrate the blood brain barrier in rodents and
protect dopaminergic neurons exposed to alpha synu-
clein preformed fibrils. In vitro data suggests these
GQDs can in fact interact with alpha synuclein fibrils,
blocking their formation and even promoting their
disaggregation [42]. If safe and sufficiently selective,
might these GQDs be the magic bullet for PD?
DISCUSSION
Research in PD has moved away from the
traditional approach of testing potential neuro-
protective agents in laboratory mouse models of
non-progressive dopamine toxicity. With efficacy
being demonstrated in models of progressive alpha
synuclein associated neurodegeneration combined
with positive data from early phase clinical trials, we
can have greater optimism that laboratory results will
translate to the clinic. It is of the highest importance
therefore that we not only robustly confirm consistent
signals of efficacy in phase 3 designs, but also that we
make appropriate preparations for success.
Drugs being repurposed for their potential neuro-
protective properties frequently lack the commercial
support required to apply for licensing. The burden
of responsibility to bring positive clinical trial data
to the attention of the regulatory authorities must be
shared among all parties with a vested interest, i.e.,
academics, charities, patient groups, and industry. A
recent initiative called “Linked Clinical Trials”, set
up by the Cure Parkinson’s Trust has involved repre-
sentatives from each sector to evaluate and prioritize
which agents are the most important to take from the
laboratory to the clinical trial setting. Bearing in mind
the eventual need to deliver successful agents to the
clinical setting, there needs to be appropriate discus-
sion of the magnitude of any beneficial effect size,
whether this is has a static or cumulative nature, the
long term safety and tolerability of the intervention,
and its overall health economic impact.
Fig. 1. Opportunities to impact on PD progression.
The divergent approaches being brought into clin-
ical trials, if any signal of effect can be robustly
confirmed, will likely also ultimately require test-
ing in combination to explore additive/synergistic
effects (Fig. 1). It is tempting to speculate that the
future patient may be recruited into research rem-
iniscent of the current state of play in HIV/cancer
fields, e.g., where following genotyping/ microbiome
testing, they are either given the curative enzyme cor-
rective therapy or randomised to receive combination
therapies rather than any/each of these alone.
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